Ampio Pharmaceuticals, Inc.

2023 Q4 Form 10-Q Financial Statement

#000155837023019022 Filed on November 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.089M $6.398M
YoY Change -67.68% -62.25%
Cash & Equivalents $4.100M $6.400M
Short-Term Investments
Other Short-Term Assets $512.0K $718.0K
YoY Change -24.26% -47.74%
Inventory $215.0K
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $5.736M $7.646M
YoY Change -56.97% -58.27%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $0.00
YoY Change -100.0% -100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL ASSETS
Total Short-Term Assets $5.736M $7.646M
Total Long-Term Assets $0.00 $0.00
Total Assets $5.736M $7.646M
YoY Change -57.79% -59.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $750.0K $459.0K
YoY Change 673.2% 110.55%
Accrued Expenses $1.230M $1.812M
YoY Change 12.33% -51.11%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.376M $2.271M
YoY Change 99.33% -42.13%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.376M $2.271M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $2.376M $2.271M
YoY Change 32.07% -54.48%
SHAREHOLDERS EQUITY
Retained Earnings -$242.5M -$240.5M
YoY Change 3.68% 3.8%
Common Stock $245.9M $245.8M
YoY Change 0.06% 0.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.360M $5.375M
YoY Change
Total Liabilities & Shareholders Equity $5.736M $7.646M
YoY Change -57.79% -59.41%

Cashflow Statement

Concept 2023 Q4 2023 Q3

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001411906
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
804674
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
804604
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35182
dei Entity Registrant Name
EntityRegistrantName
AMPIO PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-0179592
dei Entity Address Address Line1
EntityAddressAddressLine1
9800 Mount Pyramid Court, Suite 400
dei Entity Address City Or Town
EntityAddressCityOrTown
Englewood
dei Entity Address State Or Province
EntityAddressStateOrProvince
CO
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
80112
dei City Area Code
CityAreaCode
720
dei Local Phone Number
LocalPhoneNumber
437-6500
dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
AMPE
dei Security Exchange Name
SecurityExchangeName
NYSEAMER
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
832021
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6398000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12653000
CY2023Q3 us-gaap Prepaid Insurance
PrepaidInsurance
530000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
0
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
718000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
676000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
7646000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
13329000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
184000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
75000
CY2023Q3 us-gaap Assets
Assets
7646000
CY2022Q4 us-gaap Assets
Assets
13588000
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1909000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
852000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
362000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
340000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2271000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1192000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
274000
CY2023Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0
CY2022Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
44000
CY2023Q3 us-gaap Asset Retirement Obligations Noncurrent
AssetRetirementObligationsNoncurrent
0
CY2022Q4 us-gaap Asset Retirement Obligations Noncurrent
AssetRetirementObligationsNoncurrent
289000
CY2023Q3 us-gaap Liabilities
Liabilities
2271000
CY2022Q4 us-gaap Liabilities
Liabilities
1799000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
804604
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
804674
CY2023Q3 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0.0001
CY2022Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
245848000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
245728000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-240473000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-233939000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
5375000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
11789000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7646000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13588000
CY2023Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
20
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
329000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2747000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1197000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8177000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1071000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2975000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6106000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9504000
CY2023Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2022Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
1614000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
1614000
CY2023Q3 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0
CY2022Q3 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
322000
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
322000
CY2023Q3 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
CY2022Q3 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-56000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
1400000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
7658000
us-gaap Operating Expenses
OperatingExpenses
7359000
us-gaap Operating Expenses
OperatingExpenses
19617000
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
79000
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
80000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
280000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
116000
CY2023Q3 us-gaap Rental Income Nonoperating
RentalIncomeNonoperating
92000
CY2022Q3 us-gaap Rental Income Nonoperating
RentalIncomeNonoperating
0
us-gaap Rental Income Nonoperating
RentalIncomeNonoperating
213000
us-gaap Rental Income Nonoperating
RentalIncomeNonoperating
0
CY2023Q3 us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
0
CY2022Q3 us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
0
us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
288000
us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
0
CY2023Q3 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
0
CY2022Q3 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
1167000
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
0
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
5384000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
171000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1247000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
781000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5500000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1229000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-6411000
us-gaap Net Income Loss
NetIncomeLoss
-6578000
us-gaap Net Income Loss
NetIncomeLoss
-14117000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.53
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.51
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-18.73
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.53
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-10.06
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.18
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-25.88
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
804158
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
753620
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
804158
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
753616
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
804158
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
753620
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
804158
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
753616
CY2023Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
20
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
27284000
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
716000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
-79000
CY2022Q1 ampe Adjustments To Additional Paid In Capital Stock Issued Issuance Costs At Market Equity Offering Program
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsAtMarketEquityOfferingProgram
32000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-5636000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
22253000
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
423000
CY2022Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
509000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-2070000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
20097000
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
163000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-6411000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
13849000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
11789000
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
23000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-3978000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
7878000
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
53000
CY2023Q2 ampe Temporary Equity Stock Issued During Period Shares New Issues
TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
0
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1371000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
6560000
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
44000
CY2023Q3 ampe Temporary Equity Stock Redeemed During Period Shares
TemporaryEquityStockRedeemedDuringPeriodShares
0
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
0
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1229000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
5375000
CY2023Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
20
us-gaap Profit Loss
ProfitLoss
-6578000
us-gaap Profit Loss
ProfitLoss
-14117000
us-gaap Share Based Compensation
ShareBasedCompensation
120000
us-gaap Share Based Compensation
ShareBasedCompensation
793000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
122000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
865000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
1614000
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
322000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-56000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
288000
ampe Gain Loss From Change In Asset Retirement Obligation
GainLossFromChangeInAssetRetirementObligation
-5000
ampe Gain Loss From Change In Asset Retirement Obligation
GainLossFromChangeInAssetRetirementObligation
0
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
0
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
5384000
us-gaap Increase Decrease In Prepaid Insurance
IncreaseDecreaseInPrepaidInsurance
530000
us-gaap Increase Decrease In Prepaid Insurance
IncreaseDecreaseInPrepaidInsurance
0
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
43000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-366000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1058000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1219000
ampe Increase Decrease In Lease Liability
IncreaseDecreaseInLeaseLiability
-177000
ampe Increase Decrease In Lease Liability
IncreaseDecreaseInLeaseLiability
-74000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6255000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16834000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
ampe Payment Of Stock Issuance Cost Registered Direct Offering Monetary
PaymentOfStockIssuanceCostRegisteredDirectOfferingMonetary
0
ampe Payment Of Stock Issuance Cost Registered Direct Offering Monetary
PaymentOfStockIssuanceCostRegisteredDirectOfferingMonetary
32000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
79000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-111000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6255000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-16945000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12653000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
33892000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6398000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
16947000
ampe Commercial Insurance Premium Financing Agreement
CommercialInsurancePremiumFinancingAgreement
703000
ampe Commercial Insurance Premium Financing Agreement
CommercialInsurancePremiumFinancingAgreement
1159000
us-gaap Settlement Of Asset Retirement Obligations Through Noncash Payments Amount
SettlementOfAssetRetirementObligationsThroughNoncashPaymentsAmount
0
us-gaap Settlement Of Asset Retirement Obligations Through Noncash Payments Amount
SettlementOfAssetRetirementObligationsThroughNoncashPaymentsAmount
282000
CY2022Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
15
CY2023Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
20
CY2023Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
20
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Concentrations of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company has no off-balance-sheet concentrations of credit risk, such as foreign exchange contracts, option contracts or foreign currency hedging arrangements. The Company consistently maintains its cash and cash equivalent balances in the form of bank demand deposits, United States federal government backed treasury securities and fully liquid money market fund accounts with financial institutions that management believes are creditworthy. The Company periodically monitors its cash positions with, and the credit quality of, the financial institutions with which it invests. As of and subsequent to March 31, 2023, the Company no longer maintains balances in excess of federally insured limits.</p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses, and related disclosures in the financial statements and accompanying notes. The Company bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Significant items subject to such estimates and assumptions primarily include the Company’s projected current and long-term liquidity needs and availability and the amount and collectability of the insurance recovery receivable representing amounts advanced by the Company in excess of the previously paid $2.5 million self-insured retention for defense costs relating to currently pending lawsuits and the SEC investigation that is expected to be covered and paid by its directors’ and officers’ insurance. The Company develops these estimates using its judgment based upon the facts and circumstances known to it at the time.</p>
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-240500000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6400000
CY2023Q3 us-gaap Prepaid Insurance
PrepaidInsurance
500000
CY2023Q3 us-gaap Prepaid Insurance
PrepaidInsurance
530000
ampe Self Insured Retention For Pending Lawsuits Paid
SelfInsuredRetentionForPendingLawsuitsPaid
2500000
CY2023Q3 ampe Unamortized Commercial Insurance Current
UnamortizedCommercialInsuranceCurrent
517000
CY2022Q4 ampe Unamortized Commercial Insurance Current
UnamortizedCommercialInsuranceCurrent
610000
CY2023Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
136000
CY2023Q3 ampe Prepaid Deposits Current
PrepaidDepositsCurrent
34000
CY2022Q4 ampe Prepaid Deposits Current
PrepaidDepositsCurrent
34000
CY2023Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
31000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
32000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
718000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
676000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9429000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9245000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
184000
CY2022Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
347000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
122000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
865000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
459000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
97000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
737000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
157000
CY2023Q3 ampe Commercial Insurance Premiums Current
CommercialInsurancePremiumsCurrent
354000
CY2022Q4 ampe Commercial Insurance Premiums Current
CommercialInsurancePremiumsCurrent
189000
CY2023Q3 ampe Accrued Preclinical And Clinical Trials Payable Current
AccruedPreclinicalAndClinicalTrialsPayableCurrent
185000
CY2022Q4 ampe Accrued Preclinical And Clinical Trials Payable Current
AccruedPreclinicalAndClinicalTrialsPayableCurrent
89000
CY2023Q3 ampe Property Taxes Payable Current
PropertyTaxesPayableCurrent
60000
CY2022Q4 ampe Property Taxes Payable Current
PropertyTaxesPayableCurrent
74000
CY2023Q3 ampe Franchise Taxes Payable Current
FranchiseTaxesPayableCurrent
17000
CY2022Q4 ampe Franchise Taxes Payable Current
FranchiseTaxesPayableCurrent
78000
CY2022Q4 ampe Accrued Severance Payable Current
AccruedSeverancePayableCurrent
143000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
97000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
25000
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1909000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
852000
CY2023Q3 ampe Number Of Related Party Agreements
NumberOfRelatedPartyAgreements
0
CY2023Q1 ampe Gain On Elimination Of Aro Obligation
GainOnEliminationOfAroObligation
294000
CY2023Q1 ampe Asset Retirement Obligation Non Cash Gain On Derecognition Of Aro
AssetRetirementObligationNonCashGainOnDerecognitionOfAro
288000
CY2023Q1 ampe Loss On Derecognition Of Aro Asset
LossOnDerecognitionOfAroAsset
6000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
372000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
92000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
280000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
10000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
362000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
362000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
7000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
70000
us-gaap Operating Lease Cost
OperatingLeaseCost
108000
us-gaap Operating Lease Cost
OperatingLeaseCost
221000
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
53263
CY2022Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
318.80
CY2022 ampe Class Of Warrant Or Rights Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm
P3Y9M18D
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
52751
CY2023Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
320.62
ampe Class Of Warrant Or Rights Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm
P3Y29D
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
52751
CY2023Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
320.62
ampe Class Of Warrant Or Rights Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm
P3Y29D
CY2023Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0
CY2022Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
44000
CY2023Q3 ampe Unrecognized Share Based Compensation Expenses
UnrecognizedShareBasedCompensationExpenses
47000
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P1Y2M26D
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000.0
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000.0
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
804604
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
12719
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
52751
CY2023Q3 ampe Common Stock Shares Authorized Available Remaining Shares
CommonStockSharesAuthorizedAvailableRemainingShares
297929926
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
0
CY2023Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
136000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
20
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
12719
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.1683
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.1943
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0126
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0194
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
46000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
163000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
120000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
793000
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
54000
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y3M3D
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1229000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-6411000
us-gaap Net Income Loss
NetIncomeLoss
-6578000
us-gaap Net Income Loss
NetIncomeLoss
-14117000
CY2022Q3 us-gaap Warrant Down Round Feature Increase Decrease In Equity Amount1
WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1
-1167000
us-gaap Warrant Down Round Feature Increase Decrease In Equity Amount1
WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1
-5384000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1229000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7578000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6578000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19501000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
804158
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
753620
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
804158
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
753616
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
804158
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
753620
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
804158
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
753616
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.53
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.51
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-18.73
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.53
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-10.06
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.18
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-25.88
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
65917
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
72133
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
65917
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
72133

Files In Submission

Name View Source Status
ampe-20230930_cal.xml Edgar Link unprocessable
0001558370-23-019022-index-headers.html Edgar Link pending
0001558370-23-019022-index.html Edgar Link pending
0001558370-23-019022.txt Edgar Link pending
0001558370-23-019022-xbrl.zip Edgar Link pending
ampe-20230930.xsd Edgar Link pending
ampe-20230930x10q.htm Edgar Link pending
ampe-20230930x10q002.jpg Edgar Link pending
ampe-20230930xex31d1.htm Edgar Link pending
ampe-20230930xex31d2.htm Edgar Link pending
ampe-20230930xex32d1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
ampe-20230930_def.xml Edgar Link unprocessable
ampe-20230930_lab.xml Edgar Link unprocessable
ampe-20230930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
ampe-20230930x10q_htm.xml Edgar Link completed
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending